HAE - Haemonetics Corporation

NYSE - NYSE Delayed Price. Currency in USD
75.74
-0.01 (-0.01%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close75.75
Open75.61
Bid0.00 x 0
Ask0.00 x 0
Day's Range75.24 - 76.15
52 Week Range38.47 - 76.27
Volume197,671
Avg. Volume464,474
Market Cap4.048B
Beta0.95
PE Ratio (TTM)N/A
EPS (TTM)-0.33
Earnings DateMay 8, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est64.75
Trade prices are not sourced from all markets
  • Haemonetics Rides High on Plasma, Blood Center Remains Weak
    Zacks9 days ago

    Haemonetics Rides High on Plasma, Blood Center Remains Weak

    We are optimistic about Haemonetics' (HAE) improved Plasma franchise as strong end-market demand for plasma-derived biopharmaceuticals consistently drives growth for the company.

  • PR Newswire10 days ago

    Haemonetics Sets Date for Publishing Fourth Quarter Fiscal 2018 Results: May 8, 2018

    BRAINTREE, Mass. , April 10, 2018 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish fourth quarter fiscal 2018 financial results at 6:00 am EST on Tuesday ...

  • See what the IHS Markit Score report has to say about Haemonetics Corp.
    Markit10 days ago

    See what the IHS Markit Score report has to say about Haemonetics Corp.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • SRDX or HAE: Which is a Better Medical Product Stock?
    Zacks11 days ago

    SRDX or HAE: Which is a Better Medical Product Stock?

    Here we analyze the financials and fundamental factors of Haemonetics (HAE) and Surmodics (SRDX) to decide which is a better investment option.

  • Haemonetics' Plasma Tool Enhancement Gets 510(K) Clearance
    Zacks18 days ago

    Haemonetics' Plasma Tool Enhancement Gets 510(K) Clearance

    Haemonetics (HAE) witnesses steady growth in Plasma franchise, led by strong end-market demand for plasma-derived biopharmaceuticals.

  • Zacks.com highlights: Haemonetics, Alarm.com Holdings, Copart and inTEST
    Zacks18 days ago

    Zacks.com highlights: Haemonetics, Alarm.com Holdings, Copart and inTEST

    Zacks.com highlights: Haemonetics, Alarm.com Holdings, Copart and inTEST

  • ACCESSWIRE18 days ago

    Wired News – Haemonetics Received 510(k) Clearance from FDA of NexSys PCS(TM) Embedded Software

    Stock Monitor: Alphatec Holdings Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 02, 2018 / Active-Investors.com has just released a free research report on Haemonetics Corp. (NYSE: HAE ). If you ...

  • Buy These 4 Efficient Stocks for Impressive Returns
    Zacks22 days ago

    Buy These 4 Efficient Stocks for Impressive Returns

    We have considered four popular ratios in order to find efficient companies that have the potential to provide impressive returns

  • PR Newswire23 days ago

    Haemonetics Announces Regulatory Clearances of NexSys PCS™ Enhanced Software with YES™ Technology

    Embedded Software Adds Key Capability to NexSys PCS Platform BRAINTREE, Mass. , March 28, 2018 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) has received 510(k) clearance from the U.S. Food and Drug ...

  • Why Should You Add Haemonetics (HAE) to Your Portfolio Now?
    Zacks25 days ago

    Why Should You Add Haemonetics (HAE) to Your Portfolio Now?

    Market seems to be upbeat about Haemonetics' (HAE) newly-launched platform, NexSys Plasma Collection System (PCS).

  • What Could Boost Haemonetics’ Revenues in Future Years
    Market Realist29 days ago

    What Could Boost Haemonetics’ Revenues in Future Years

    Haemonetics (HAE) expects its transfusion management business to grow at a compound annual growth rate (or CAGR) in the low to mid teens. Haemonetics has planned to opt for a key account strategy. The company aims to strengthen its worldwide presence by expanding its global sales team and partnering with other software vendors and players in this segment, like Helmer.

  • HAE Focuses on Revitalizing Cell Salvage Business in Fiscal 2018
    Market Realistlast month

    HAE Focuses on Revitalizing Cell Salvage Business in Fiscal 2018

    Although Haemonetics expects the overall cell salvage market to grow at a CAGR (compound average growth rate) in the low single digits, the company is focused on significantly improving its existing product line and rapidly increasing its market share in the fastest-growing markets. The above diagram shows the global market shares of Haemonetics and its competitors Fresenius (FMS), Medtronic (MDT), and LivaNova (LIVN) in the cell salvage (or auto transfusion) business in fiscal 2017. Haemonetics has improved on its older Cell Saver product in terms of connectivity and overall programming and has launched the Cell Saver Elite platform.

  • The Hospital Business Remains 1of HAE’s Key Growth Drivers
    Market Realistlast month

    The Hospital Business Remains 1of HAE’s Key Growth Drivers

    In fiscal 3Q18, Haemonetics (HAE) reported revenue of close to $46.7 million in its hospital business, a YoY (year-over-year) rise of ~9.1%. The hemostasis management franchise within the hospital business reported revenue of close to $19.9 million in fiscal 3Q18, a YoY rise of ~17.6%. The cell processing franchise, which is also part of the hospital business, reported revenue of close to $26.8 million in fiscal 3Q18, a YoY rise of ~3.5%.

  • HAE Is Well Placed to Compete in Plasma Collection in Fiscal 2018
    Market Realistlast month

    HAE Is Well Placed to Compete in Plasma Collection in Fiscal 2018

    Haemonetics (HAE) is focused on initiating the commercial launch of its innovative NexSys PCS device coupled with its embedded firmware, NexLynk DMS, in 2H18. Although the combination of the NexSys PCS device and the NexLynk software is designed to result in a completely integrated and optimal bidirectional system, NexSys PCS supports an open architecture and can work with any other donor management software (or DMS). NexLynk software, however, has been designed to work optimally with NexSys PCS, and it thus eliminates the need for the translation of data between the device and the software.

  • Plasma Remains an Attractive Business for HAE
    Market Realistlast month

    Plasma Remains an Attractive Business for HAE

    In fiscal 2017, Haemonetics (HAE) earned almost 46% of its total revenue from its plasma franchise. The company has earned ~48.4% of its total revenue from its plasma franchise YTD (year-to-date) in fiscal 2018. Approximately 91% of the plasma segment’s total revenue in fiscal 2017 was attributable to the sale of disposables.

  • Plasma Continues to Drive Strong Growth for HAE in Fiscal 2018
    Market Realistlast month

    Plasma Continues to Drive Strong Growth for HAE in Fiscal 2018

    In fiscal 3Q18, Haemonetics (HAE) reported revenue of close to $113.1 million, a YoY (year-over-year) rise of ~4.1%. Haemonetics has earned revenue of nearly $324.4 million from the sale of its products in the plasma franchise YTD (year-to-date) in fiscal 2018, which reflects a YoY rise of ~4.7%. The franchise has reported organic revenue growth of close to 6% YTD in fiscal 2018, and it’s expected to continue witnessing robust growth owing to solid demand for drugs based on human plasma.

  • HAE Expects a Modest Net Profit Margin Expansion in Fiscal 2018
    Market Realistlast month

    HAE Expects a Modest Net Profit Margin Expansion in Fiscal 2018

    On its fiscal 3Q18 earnings conference call, Haemonetics (HAE) increased the guidance for its fiscal 2018 adjusted EPS (earnings per share) by ~$0.12 to the range $1.80–$1.90. Haemonetics has calculated this EPS guidance by assuming a positive impact from its overperformance in fiscal 3Q18 and a negative impact from its anticipated investments in fiscal 4Q18. Excluding the impact of its restructuring and turnaround expenses, the company expects $125 million worth of free cash flow in fiscal 2018.

  • HAE Is Expected to Report Flat Revenue Performance in Fiscal 2018
    Market Realistlast month

    HAE Is Expected to Report Flat Revenue Performance in Fiscal 2018

    Haemonetics (HAE) expects to report fiscal 2018 revenue in line with what it witnessed in fiscal 2017. The company also expects to witness 6% YoY revenue growth in its hospital business, lower than its previously projected revenue growth rate range of 7%–10%. Haemonetics, however, expects its blood center business to report a 7% YoY fall in fiscal 2018 revenue, which is at the lower end of its expectation of a fall of 7%–10%.

  • Analysts’ Recommendations for Haemonetics and Peers in March 2018
    Market Realistlast month

    Analysts’ Recommendations for Haemonetics and Peers in March 2018

    What's the Word on Haemonetics in 2018?Financial performance in fiscal 3Q18

  • Cerus (CERS) Looks Good: Stock Adds 9.5% in Session
    Zackslast month

    Cerus (CERS) Looks Good: Stock Adds 9.5% in Session

    Shares of Cerus (CERS) rose 9.5% on Friday

  • Zacks.com highlights: Copart, Haemonetics, Surmodics, Alarm.com Holdings and ConocoPhillips
    Zackslast month

    Zacks.com highlights: Copart, Haemonetics, Surmodics, Alarm.com Holdings and ConocoPhillips

    Zacks.com highlights: Copart, Haemonetics, Surmodics, Alarm.com Holdings and ConocoPhillips

  • 5 Top-Ranked Efficient Stocks to Boost Your Portfolio
    Zackslast month

    5 Top-Ranked Efficient Stocks to Boost Your Portfolio

    A company with a favorable efficiency level will provide impressive returns irrespective of market conditions

  • See what the IHS Markit Score report has to say about Haemonetics Corp.
    Markitlast month

    See what the IHS Markit Score report has to say about Haemonetics Corp.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, growth of ETFs holding HAE is favorable, with net inflows of $4.35 billion.

  • 3 Stocks to Gain as Trump Pulls Plug on Infamous MedTech Tax
    Zackslast month

    3 Stocks to Gain as Trump Pulls Plug on Infamous MedTech Tax

    Here take a quick look on three major MedTech companies that are going to make the best out of the recent Tax-Repeal upheaval.

  • Haemonetics (HAE) Up 4.2% Since Earnings Report: Can It Continue?
    Zackslast month

    Haemonetics (HAE) Up 4.2% Since Earnings Report: Can It Continue?

    Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.